Adult-onset Still's disease
- For the juvenile onset form see Systemic-onset juvenile idiopathic arthritis
|Adult-onset Still's disease|
Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain, and a distinctive salmon-colored bumpy rash. The disease is considered a diagnosis of exclusion. Levels of the iron-binding protein ferritin may be extremely elevated with this disorder. AOSD may present in a similar manner to other inflammatory diseases and to autoimmune diseases, which must be ruled out before making the diagnosis.
Prognosis is usually favorable but manifestations of the disease affecting the lungs, heart, or kidneys may occasionally cause severe life-threatening complications. It is treated first with corticosteroids such as prednisone. Medications that block the action of interleukin-1, such as anakinra, can be effective treatments when standard steroid treatments are insufficient.
Signs and symptoms
The disease typically presents with joint pain, high fevers, a salmon-pink macular or maculopapular rash, enlargement of the liver and spleen, swollen lymph nodes, and a neutrophil-predominant increased white blood cell count in the blood. Tests for rheumatoid factor and anti-nuclear antibodies are usually negative and serum ferritin is markedly elevated. Patients experiencing a flare-up from Adult-onset Still's disease usually report extreme fatigue, swelling of the lymph nodes and, less commonly, fluid accumulation in the lungs and heart. In rare cases, AOSD can cause aseptic meningitis and sensorineural hearing loss.
The cause of adult-onset Still's disease is unknown, but it presumably involves interleukin-1 (IL-1), since medications that block the action of IL-1β are effective treatments. Interleukin-18 is expressed at high levels.
The diagnosis is clinical, not based upon serology. At least seven sets of diagnostic criteria have been devised, however the Yamaguchi criteria have the highest sensitivity. Diagnosis requires at least five features, with at least two of these being major diagnostic criteria.
|Major criteria||Minor criteria|
|Fever of at least 39 °C for at least one week||Sore throat|
|Arthralgias or arthritis for at least two weeks||Lymphadenopathy|
|Nonpruritic salmon-colored rash (usually over trunk or extremities while febrile)||Hepatomegaly or splenomegaly|
|Leukocytosis (10,000/microL or greater), with granulocyte predominance||Abnormal liver function tests|
|Negative tests for antinuclear antibody and rheumatoid factor|
People with AOSD generally experience one of two patterns in the disease:
- a debilitating pattern of fevers, pain, and other systemic symptoms, or
- a somewhat less aggressive pattern, in which the main symptom is arthritis and chronic joint pain.
One set of 21 adult-onset Still's disease patients were divided into four types, according to clinical course patterns. These included monocyclic systemic disease, polycyclic systemic disease, chronic articular monocyclic systemic disease, and chronic articular polycyclic systemic disease. People with chronic articular disease and polyarticular disease were at higher risk to develop disabling arthritis.
Adult-onset Still's disease is treated with anti-inflammatory medications. Steroids such as prednisone are used to treat severe symptoms of Still's. Other commonly used medications include hydroxychloroquine, penicillamine, azathioprine, methotrexate, etanercept, anakinra, tocilizumab cyclophosphamide, adalimumab, rituximab, and infliximab.
Newer medications target interleukin-1 (IL-1), particularly IL-1β. A randomized, multicenter trial reported better outcomes in a group of 12 patients treated with anakinra than in a group of 10 patients taking other disease-modifying antirheumatic drugs. Other anti-IL1 drugs include canakinumab which selectively binds IL-1β and rilonacept which blocks both IL-1A and IL-1β. The monoclonal anti-IL6 antibody tocilizumab is another treatment option as effective as anakinra.
Adult-onset Still's Disease is rare and has been described all over the world. The number of new cases per year is estimated to be 1.6 per 1,000,000 population. The number of people currently affected is estimated at 1.5 cases per 100,000–1,000,000 population. Onset is most common in two age ranges, between ages 16–25 and between ages of 36–46 years.
- Akkara Veetil BM, Yee AH, Warrington KJ, Aksamit AJ Jr, Mason TG (December 2012). "Aseptic meningitis in adult onset Still's disease". Rheumatol Int. 32 (12): 4031–4. doi:10.1007/s00296-010-1529-8. PMID 20495923.
- Colafrancesco, Serena; Priori, Roberta; Alessandri, Cristiano; Perricone, Carlo; Pendolino, Monica; Picarelli, Giovanna; Valesini, Guido (2012). "IL-18 Serum Level in Adult Onset Still's Disease: A Marker of Disease Activity". International Journal of Inflammation. 2012: 1–6. doi:10.1155/2012/156890. PMC . PMID 22762008.
- Gerfaud-Valentin, Mathieu; Jamilloux, Yvan; Iwaz, Jean; Sève, Pascal (July 2014). "Adult-onset Still's disease". Autoimmunity Reviews. 13 (7): 708–722. doi:10.1016/j.autrev.2014.01.058. ISSN 1873-0183. PMID 24657513.
- Sugiura, T; Kawaguchi, Y; Harigai, M; Terajima-Ichida, H; Kitamura, Y; Furuya, T; Ichikawa, N; Kotake, S; Tanaka, M; Hara, M; Kamatani, N (Nov 2002). "Association between adult-onset Still's disease and interleukin-18 gene polymorphisms". Genes and immunity. 3 (7): 394–9. doi:10.1038/sj.gene.6363922. PMID 12424620.
- Jamilloux, Y; Gerfaud-Valentin, M; Martinon, F; Belot, A; Henry, T; Sève, P (February 2015). "Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart". Immunologic research. 61 (1–2): 53–62. doi:10.1007/s12026-014-8561-9. PMID 25388963.
- Efthimiou P, Kontzias A, Ward CM, Ogden NS (June 2007). "Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?". Nat Clin Pract Rheumatol. 3 (6): 328–35. doi:10.1038/ncprheum0510. PMID 17538564.
- Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T (1992). "Preliminary criteria for classification of adult Still's disease". J. Rheumatol. 19 (3): 424–30. PMID 1578458.
- Cush, JJ; Medsger TA Jr; Christy, WC; Herbert, DC; Cooperstein, LA (Feb 1987). "Adult-onset Still's disease. Clinical course and outcome". Arthritis and Rheumatism. 30 (2): 186–194. doi:10.1002/art.1780300209. PMID 3827959.
- Jamilloux, Y; Gerfaud-Valentin, M; Henry, T; Sève, P (22 December 2014). "Treatment of adult-onset Still's disease: a review". Therapeutics and clinical risk management. 11: 33–43. doi:10.2147/TCRM.S64951. PMC . PMID 25653531.
- Nordström D; Knight A; Luukkainen R; van Vollenhoven R; et al. (Oct 2012). "Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study". J. Rheumatol. 39 (10): 2008–11. doi:10.3899/jrheum.111549. PMID 22859346.
- Cecilia Giampietro; Bruno Fautrel (2012). "Review Article: Anti-Interleukin-1 Agents in Adult Onset Still's Disease". International Journal of Inflammation. 2012 (317820): 317820. doi:10.1155/2012/317820. PMC . PMID 22611515.
- Al-Homood, I. A. (2014-01-01). "Biologic treatments for adult-onset Still's disease". Rheumatology. 53 (1): 32–38. doi:10.1093/rheumatology/ket250. ISSN 1462-0324.
- Luthi F, Zufferey P, Hofer MF, So AK (2002). ""Adolescent-onset Still's disease": characteristics and outcome in comparison with adult-onset Still's disease". Clin. Exp. Rheumatol. 20 (3): 427–30. PMID 12102485.
- Owlia MB, Mehrpoor G (2009). "Adult – onset Still's disease : A review". Indian J Med Sci. 63 (5): 207–21. doi:10.4103/0019-5359.53169. PMID 19584494.
- synd/1773 at Who Named It?
- G. F. Still. A special form of joint disease met with in children. Doctoral dissertation, Cambridge, 1896.
- Kopeć-Mędrek, Magdalena; Widuchowska, Małgorzata; Kucharz, Eugeniusz J. (2016). "Calprotectin in rheumatic diseases: a review". Reumatologia. 54 (6): 306–309. doi:10.5114/reum.2016.64907. ISSN 0034-6233. PMC . PMID 28115781.
- "Adult-onset Still's disease". Genetic and Rare Diseases Information Center (GARD).